Role of tipranavir in treatment of patients with multidrug-resistant HIV

Abstract

Joshua D Courter1,2, Colleen J Teevan1, Michael H Li1, Jennifer E Girotto1,2, Juan C Salazar1,2,31University of Connecticut School of Pharmacy, Storrs, 2Connecticut Children’s Medical Center, Hartford, 3University of Connecticut School of Medicine, Hartford, Connecticut, USAAbstract: The worldwide emergence of multidrug-resistant human immunodeficiency virus (HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have become available for treatment. It is important to assess how these new ARVs might be most judiciously used, paying close attention to viral susceptibility patterns, pharmacodynamic parameters, and the likelihood that patients will adhere to their therapy. Herein we review published material in Medline, EMBASE, and ISI for each antiretroviral agent/classes currently approved and summarize the available data on their efficacy, safety, and pharmacologic parameters. We focus on the role of tipranavir, a recently approved nonpeptidic PI, for treating HIV-infected children, adolescents, and adults with a history of multidrug-resistant HIV.Keywords: tipranavir, HIV, multidrug resistance